Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma 5Neoplasms 2Multiple Myeloma 2Recurrence 1Primary Myelofibrosis 1Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 9Filgrastim 7Specimen Handling 6X-Rays 5Rituximab 5Radiotherapy 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Psychiatric Rehabilitation 4Nuclear Medicine Department, Hospital 4Methotrexate 4Etoposide 4Cyclophosphamide 4Biopsy 4etoposide phosphate 3Pemetrexed 3Melphalan 3Cytarabine 3Carboplatin 3tazemetostat 2sargramostim 2olaparib 2larotrectinib 2erdafitinib 2ensartinib 2Vincristine 2Vemurafenib 2Topotecan 2Thiotepa 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × ridaforolimus × Lymphoid × Clear all
NCT00704054 2015-02-13

A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
15 enrolled
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡